Capricor Therapeutics (CAPR) Tops Q1 EPS by 1c

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of $0.31, $0.01 better than the analyst estimate of $0.30. Revenue for the quarter came in at $2.98 million versus the consensus estimate of $500 thousand.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Goldman Sachs Assumes Klaviyo Inc (KVYO) at Buy
• JPMorgan Downgrades Wipro Ltd. (WPRO:IN) (WIT) to Underweight